The Center for Advanced Medical Engineering and Informatics, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
Stat Med. 2010 Sep 20;29(21):2169-79. doi: 10.1002/sim.3972.
Clinical trials often employ two or more primary efficacy endpoints. One of the major problems in such trials is how to determine a sample size suitable for multiple co-primary correlated endpoints. We provide fundamental formulae for the calculation of power and sample size in order to achieve statistical significance for all the multiple primary endpoints given as binary variables. On the basis of three association measures among primary endpoints, we discuss five methods of power and sample size calculation: the asymptotic normal method with and without continuity correction, the arcsine method with and without continuity correction, and Fisher's exact method. For all five methods, the achieved sample size decreases as the value of association measure increases when the effect sizes among endpoints are approximately equal. In particular, a high positive association has a greater effect on the decrease in the sample size. On the other hand, such a relationship is not very strong when the effect sizes are different.
临床试验通常采用两个或多个主要疗效终点。在这类试验中,主要问题之一是如何确定适合多个主要相关终点的样本量。我们提供了基本公式,用于计算给定为二项变量的所有多个主要终点的功效和样本量,以达到统计学意义。基于主要终点之间的三个关联度量,我们讨论了五种功效和样本量计算方法:具有和不具有连续性校正的渐近正态法、具有和不具有连续性校正的反正弦法以及 Fisher 精确法。对于所有五种方法,当终点之间的效应大小大致相同时,随着关联度量值的增加,实际获得的样本量会减少。特别是,高正关联对样本量的减少有更大的影响。另一方面,当效应大小不同时,这种关系不是很强。